Publications by authors named "Mamta Garg"

Claim this Profile
M
Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline.
Matthew Jenner, Kevin Boyd, Satarupa Choudhuri, Christopher Parrish, Mamta Garg

Br J Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline.
Anna L Godfrey, Alesia A Khan, Andrew McGregor, Andrew J Innes, Mohammed Altohami, Mamta Garg

Br J Haematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cross-sectional study about knowledge, attitude and practice regarding anemia among school going adolescent girls in Naila, Jaipur, Rajasthan.
Mamta Garg, Sunil Singh Rathore, Vedant Garg, Raghvendra Bagla

Int J Adolesc Med Health· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics, Treatment Patterns, and Outcomes of Patients with Multiple Myeloma, Including Those Who are Triple-Class Exposed: A Retrospective Cohort Study in England Using National Cancer Registry Data.
Carmen Tsang, Kellyn Arnold, Charles Duffield, Stavros Oikonomou, Thomas Price, Mamta Garg

EJHaem· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial.
Vania Hungria, Paweł Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, Mamta Garg

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.
Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Mamta Garg

Lancet Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Busulphan Based on Dosing Patterns in the Real-World Management of Myeloproliferative Neoplasms.
Ali Mahdi, Alexandros Rampotas, Patrick Roberts, Joanna Stokes, Eamon Mahdi, Mamta Garg

EJHaem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.
Nichola Cooper, A J Gerard Jansen, Robert Bird, Jiří Mayer, Michelle Sholzberg, Mamta Garg

Am J Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Gordon Cook, A John Ashcroft, Ethan Senior, Catherine Olivier, Anna Hockaday, Mamta Garg

Lancet Haematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, Mamta Garg

N Engl J Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guideline for the management of conception and pregnancy in thalassaemia syndromes: A British Society for Haematology Guideline.
Farrukh T Shah, Sarah Nicolle, Mamta Garg, Shivan Pancham, Gidon Lieberman

Br J Haematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Jahanzaib Khwaja, Joshua Bomsztyk, Maria Atta, Ceri Bygrave, Adam Forbes, Mamta Garg

Br J Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention and treatment of infection in patients with an absent or hypofunctional spleen: A British Society for Haematology guideline.
Shamez N Ladhani, Savio Fernandes, Mamta Garg, Ray Borrow, Simon de Lusignan

Br J Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia.
David J Kuter, Jiri Mayer, Merlin Efraim, Lachezar H Bogdanov, Ross Baker, Mamta Garg

Blood Adv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline.
Austin Kulasekararaj, Jamie Cavenagh, Inderjeet Dokal, Theodora Foukaneli, Shreyans Gandhi, Mamta Garg

Br J Haematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.
Donal P McLornan, Anna L Godfrey, Anna Green, Rebecca Frewin, Siamak Arami, Mamta Garg

Br J Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib.
Alex Rampotas, Luke Carter-Brzezinski, Tim C P Somervaille, James Forryan, Fotios Panitsas, Mamta Garg

Blood· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The management of myelofibrosis: A British Society for Haematology Guideline.
Donal P McLornan, Bethan Psaila, Joanne Ewing, Andrew Innes, Siamak Arami, Mamta Garg

Br J Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.
Sriram Ravichandran, Andrew Hall, Matthew Jenner, Mamta Garg, Bhuvan Kishore

Amyloid· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma.
Martin F Kaiser, Andrew Hall, Katrina Walker, Amy Sherborne, Ruth M De Tute, Mamta Garg

J Clin Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.
Claire N Harrison, Jyoti Nangalia, Rebecca Boucher, Aimee Jackson, Christina Yap, Mamta Garg

J Clin Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rare cause of pericardial effusion: 'Erdheim-Chester disease'.
Haider Imtiaz, Mohsin Hussein, Daniel Chan, Mamta Garg

BMJ Case Rep· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma.
Jessica Kendall, Andrew Hall, Sadie Roberts, Sarah Brown, Kevin Boyd, Mamta Garg

BMJ Open· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.
Thomas Martin, Joseph Mikhael, Roman Hajek, Kihyun Kim, Kenshi Suzuki, Mamta Garg

Blood Adv· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
David J Kuter, Merlin Efraim, Jiri Mayer, Marek Trněný, Vickie McDonald, Mamta Garg

N Engl J Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis